VitaSpring Biomedical Co. Ltd.

What they do

VitaSpring markets cell-derived wellness, skincare and anti-aging products based on PCMSC, a mesenchymal stem cell derived from placental tissue, and exosome materials derived from those cells. It does not manufacture or own the underlying technology: products are made by a single related-party supplier in Taiwan that owns the cell culture processes, media and formulations, and the company holds no patents or pending applications. Sales were suspended after fiscal 2022 while the supplier requalified its process and target-market regulation stayed unsettled.

Revenue drivers

• Wellness and anti-aging product sales (historical) — Cumulative revenue of approximately $5.9 million, including $5,613,200 in fiscal 2022; no revenue has been recorded since, and sales were suspended after that year.
• Membership subscription program (planned) — A longevity-market subscription in Taiwan, Mainland China and Southeast Asia where members receive product by membership level; as of the latest 10-Q no agent agreements had been signed.
• Clinic supply arrangements (planned) — Proposed supply of products to medical clinics serving the longevity market for their existing patients; no clinic supply arrangements had been entered into as of the latest 10-Q.
• Licensing and stem cell bank (long-term) — Stated longer-term objectives of a stem cell bank and licensable data and processes; no revenue or spending is currently attributed to these.

Recent performance

Fiscal 2026 (ended January 31, 2026) revenue was zero, matching fiscal 2025, and net loss narrowed to $415,368 from $774,922. Operating expenses fell to $385,411 from $679,914, driven by lower professional fees ($125,673 vs. $180,700) and the absence of stock-based compensation ($0 vs. $109,911) and lease expenses ($0 vs. $99,171). Income tax expense of $29,957 and $95,008 in fiscal 2026 and 2025 was interest and penalties on fiscal 2022 obligations, not tax on current income. The most recent quarterly periods (through July 31, 2026) also show zero revenue, with total assets of $14,822, total liabilities of $4.7 million and shareholder equity of negative $4.7 million.

Strategy

Management is re-establishing sales channels rather than pursuing short-term sales, building a membership subscription program and a clinic supply relationship in Taiwan, Mainland China and Southeast Asia. The company has no written supply agreement or exclusivity with its related-party supplier; on May 18, 2026 it signed an agreement deferring $2,411,000 of payables for 24 months without interest, and the supplier said future supply would not be conditioned on repayment. Longer-term plans include a GTP-standard stem cell bank and X.msc/X.exosome clinical work, which management projects could reach limited hospital implementation in roughly five years. Management states substantial doubt about going concern and says it lacks liquidity for the next twelve months without additional financing.

Risks

• Going concern — Management concluded substantial doubt exists about continuing as a going concern within twelve months, with $13,367 of cash at July 31, 2026 against $4.7 million of liabilities, and no revenue since fiscal 2022.
• Single related-party supplier — All products come from one Taiwan supplier that owns the cell culture processes and formulations and is wholly owned by shareholders holding more than 20% of the company, with no written supply agreement or exclusivity.
• No validated science or R&D — The company conducted no research and development in fiscal 2026 or 2025, has no patents, and its X.msc and exosome claims are based on preliminary internal observations not independently validated or reviewed by regulators.
• No operations or approvals — As of January 31, 2026 the company was not manufacturing, not running clinical trials, had incurred no R&D expenses, and had obtained no FDA or other regulatory approvals.

Outlook

Management is focused on reopening commercial sales through the planned membership subscription and clinic supply channels and on completing the supplier requalification and regulatory clarity in its target markets. It states it needs substantial additional capital to transition to operational status and does not have the liquidity to fund the next twelve months without financing. No timelines or signed customer agreements have been disclosed.